Omvoh was approved in 2023 to treat moderate to severe ulcerative colitis in adults. The medicine targets interleukin (IL)-23 and contains the active ingredient mirikizumab-mrkz.

Current treatment guidelines support the use of Tremfya as an option in adults with moderate to severe ulcerative colitis. Tremfya is considered an "intermediate to higher efficacy" medicine by ...

An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve clinical remission, a phase 2 trial has found.